ABBV

SEC source: 0001415889-24-004415 · form4-02202024_050201.xml · derivative · entry 5

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,472

Underlying: Common Stock · 113,472 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,824 on February 15, 2025, 37,824 on February 15, 2026, and 37,824 on February 15, 2027.

SEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 4

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 772,159

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,859

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 708,651

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004415 · form4-02202024_050201.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 669,629

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,888

Underlying: Common Stock · 59,888 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,602

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,572

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,426

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,210

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004417 · form4-02202024_050210.xml · derivative · entry 6

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,085

Underlying: Common Stock · 39,085 shares

Expires 2034-02-14

F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,029 on February 15, 2025, 13,028 on February 15, 2026, and 13,028 on February 15, 2027.

SEC source: 0001415889-24-004417 · form4-02202024_050210.xml · nonDerivative · entry 4

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,901

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004417 · form4-02202024_050210.xml · nonDerivative · entry 3

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,633

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004417 · form4-02202024_050210.xml · nonDerivative · entry 2

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,793

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004417 · form4-02202024_050210.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,983

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004418 · form4-02202024_050219.xml · derivative · entry 5

Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,912

Underlying: Common Stock · 18,912 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,304 on February 15, 2025, 6,304 on February 15, 2026, and 6,304 on February 15, 2027.

SEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 4

Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,901

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 3

Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,553

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 2

Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,203

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 1

Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,651

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004419 · form4-02202024_050224.xml · derivative · entry 5

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,520

Underlying: Common Stock · 31,520 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,507 on February 15, 2025, 10,507 on February 15, 2026, and 10,506 on February 15, 2027.

SEC source: 0001415889-24-004419 · form4-02202024_050224.xml · nonDerivative · entry 4

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,065

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004419 · form4-02202024_050224.xml · nonDerivative · entry 3

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,153

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004419 · form4-02202024_050224.xml · nonDerivative · entry 2

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,755

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004419 · form4-02202024_050224.xml · nonDerivative · entry 1

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,609

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004420 · form4-02202024_050232.xml · derivative · entry 5

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,324

Underlying: Common Stock · 23,324 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027.

SEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 4

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,173

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,381

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,537

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,399

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative return on invested capital. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004421 · form4-02202024_050235.xml · derivative · entry 5

Thakkar Roopal · CIK 0002004979 · SVP, CMO, GLOBAL THERAPEUTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,868

Underlying: Common Stock · 13,868 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027.

SEC source: 0001415889-24-004421 · form4-02202024_050235.xml · nonDerivative · entry 4

Thakkar Roopal · CIK 0002004979 · SVP, CMO, GLOBAL THERAPEUTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,173

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004421 · form4-02202024_050235.xml · nonDerivative · entry 3

Thakkar Roopal · CIK 0002004979 · SVP, CMO, GLOBAL THERAPEUTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,381

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004421 · form4-02202024_050235.xml · nonDerivative · entry 2

Thakkar Roopal · CIK 0002004979 · SVP, CMO, GLOBAL THERAPEUTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,537

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004421 · form4-02202024_050235.xml · nonDerivative · entry 1

Thakkar Roopal · CIK 0002004979 · SVP, CMO, GLOBAL THERAPEUTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,399

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004422 · form4-02202024_050245.xml · derivative · entry 5

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,934

Underlying: Common Stock · 6,934 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,312 on February 15, 2025, 2,311 on February 15, 2026, and 2,311 on February 15, 2027.

SEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 4

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,211

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 3

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,607

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 2

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,131

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 1

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,243

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004423 · form4-02202024_100216.xml · derivative · entry 5

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,433

Underlying: Common Stock · 21,433 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,145 on February 15, 2025, 7,144 on February 15, 2026, and 7,144 on February 15, 2027.

SEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 4

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,756

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 3

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,122

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 2

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,602

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,560

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004426 · form4-02202024_050201.xml · derivative · entry 7

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,313

Underlying: Common Stock · 29,313 shares

Expires 2034-02-14

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,771 on February 15, 2025, 9,771 on February 15, 2026, and 9,771 on February 15, 2027.

SEC source: 0001415889-24-004426 · form4-02202024_050201.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,944

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004426 · form4-02202024_050201.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,884

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004426 · form4-02202024_050201.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,504

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004426 · form4-02202024_050201.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,946

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.